Apnimed secures up to $150 million from HealthCare Royalty to support commercialization and planned NDA submission for AD109, an oral therapy for obstructive sleep apnea.
Written By: Sana Khan, BPharm
Reviewed By: Pharmacally Editorial Team
Financing Structured Around Regulatory and Commercial Milestones
Apnimed, Inc. announced it has entered into a senior secured credit facility for up to $150 million with funds managed by HealthCare Royalty Partners to support commercial readiness activities and the planned U.S. launch of its lead obstructive sleep apnea (OSA) candidate, AD109, if approved by the U.S. Food and Drug Administration. The financing is structured in three tranches tied to regulatory and commercial milestones.
Under the agreement, Apnimed will receive $50 million at closing. A second $50 million tranche will become available upon FDA approval of AD109, while a third $50 million tranche can be accessed upon achievement of a pre-specified sales milestone, subject to customary conditions.
The financing includes an interest-only period of four years, extendable to five years if the company achieves a specified net sales milestone. Apnimed also agreed to pay a synthetic royalty representing a low single-digit percentage of net sales of AD109 and certain other revenues.
Companies Highlight Commercialization Strategy for AD109
Larry Miller, Chief Executive Officer of Apnimed said the financing strengthens financial flexibility and supports preparations for potential U.S. commercialization of AD109. HealthCare Royalty Partners stated that Apnimed’s regulatory and commercial strategy for AD109, an oral therapy designed to address underlying neuromuscular causes of OSA, positions the company to impact treatment options for patients.
Phase 3 SynAIRgy and LunAIRo Trials Support Planned NDA
Apnimed previously reported positive results from the pivotal Phase 3 SynAIRgy and LunAIRo trials evaluating AD109. These data are expected to support a planned New Drug Application submission to the FDA later this quarter.
AD109: Oral Therapy Targeting Neuromuscular Cause of OSA
AD109 is designed as a once-daily oral therapy intended to improve oxygenation during sleep by targeting neuromuscular mechanisms that contribute to upper airway collapse in OSA. The investigational therapy combines aroxybutynin, a novel antimuscarinic, with atomoxetine, a selective norepinephrine reuptake inhibitor. The combination is intended to address the underlying neuromuscular dysfunction associated with obstructive sleep apnea.
Obstructive Sleep Apnea: High Prevalence and Unmet Need
Obstructive sleep apnea is a chronic sleep-related breathing disorder characterized by repeated upper airway collapse during sleep, leading to intermittent oxygen deprivation. The condition is driven by overlapping neuromuscular dysfunction and anatomical factors. It affects an estimated 80 million people in the United States and approximately one billion individuals worldwide. Untreated OSA is associated with increased risk of cardiovascular, neurocognitive, and cardiometabolic complications, while many diagnosed patients remain untreated.
Reference
Apnimed Secures Up to $150 Million in Debt Financing with HealthCare Royalty Partners to Support Planned AD109 Commercial Launch, 06 April 2026, Apnimed Secures Up to $150 Million in Debt Financing with HealthCare Royalty Partners to Support Planned AD109 Commercial Launch – Apnimed
About the Writer
Sana Jamil Khan is a B.Pharm graduate with a strong interest in medical writing and scientific communication. Her work focuses on interpreting clinical research, exploring developments in pharmaceutical science, and presenting complex medical information in a clear and accessible manner. She is particularly interested in topics related to human clinical studies, drug safety observations, and emerging therapeutic research.